期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

缬沙坦口服纳米骨架制剂的处方筛选及体外溶出评价考察 被引量：2

Preparation and dissolution of valsartan nano-matrix oral drug delivery system
原文传递
导出
摘要 目的通过纳米骨架给药技术提高难溶性药物缬沙坦的体外溶出度。方法应用旋转蒸发法制备缬沙坦口服纳米骨架制剂,以溶出度为评价指标,用正交设计筛选处方,优化处方的纳米骨架制剂与市售制剂在不同pH介质中的体外溶出行为进行对比研究,并对优化处方进行形态学观察。结果筛选的优化处方为:Valsartan:Sylysia 350:Eudragit L100-55=1:2:2。与市售制剂相比,优化处方的纳米骨架制剂在pH=1.2、pH=4.5和水中有更好的溶出行为。结论纳米骨架制剂能够提高缬沙坦的体外溶出,具有一定的应用前景。 Objective To prepare Silica 350 loaded valsartan nano-matrix drug delivery system to increase the dissolution. Methods The valsartan nano-matrix oral drug delivery system was prepared by rotary-film evaporation. Orthogonal experiment was designed to screen the optimal formulation： valsartan ： Sylysia 350 ： Eudragit L100-55 = 1 ： 2 ： 2. Different dissolutions were investigated with different pH media. Results The dissolution of the optimal formulation in pH = 1.2, pH = 4.5 and water was better than that of commercial product Diovan. Conclusion Valsartan nanomatrix oral drug delivery system has better dissolution than Diovan.
作者 刘婧琳 林佳亮 王小哲 陈晴 陈大为 代文兵 张强
机构地区 沈阳药科大学药学院 北京大学药学院
出处 《中南药学》 CAS 2015年第9期930-934,共5页 Central South Pharmacy
关键词 药剂学 纳米骨架 旋转蒸发法 溶出度 缬沙坦 pharmaceutics nano-matrix rotary-film evaporation dissolution valsartan
分类号 R94 [医药卫生—药剂学]
  • 相关文献

参考文献14

  • 1Park YJ,Lee HK,Im YB,et al.Improved pH-independent dissolution and oral absorption of valsartan via the preparation of solid dispersion[J].Arch Pharm Res,2010,33(8):1235-1240.
  • 2Ma QP,Sun HR,Che EX,et al.Uniform nano-sized valsartan for dissolution and bioavailability enhancement:influence of particle size and crystalline state[J].Int J Pharm,2013,441(1-2):75-81.
  • 3Yan YD,Sung JH,Kim KK,et al.Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes[J].Int J Pharm,2012,422(1-2):202-210.
  • 4Sumit K,Rajan J,Jie S,et al.Burgess.Formulation and Performance of Danazol Nano-crystalline suspensions and spray dried powders[J].Pharm Res,2015,32(5):1694-1703.
  • 5Flesch G,Müller P,Lloyd P.Absolute bioavailability and pharmacokinetics of valsartan,an angiotensinⅡreceptor antagonist in man[J].Eur J Clin Pharmacol,1997,52(2):115-120.
  • 6Muller RH,Schmidt S,Buttle.Sol Emuls-novel technology for the formulation of i.v.emulsions with poorly soluble drugs[J].Int J Pharm,2004,269(2):293-302.
  • 7Majumdar AK,Howard L,Goldberg MR.Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers[J].J Clin Pharmacol,2006,46(3):291-300.
  • 8Jia ZR,Lin P,Xiang Y,et al.A novel nanomatrix system consisted of colloidal silica and pH-sensitive polymethylacrylate improves the oral bioavailability of fenofibrate[J].Eur J Pharm Biopharm,2011,79(1):126-134.
  • 9Takeuchi H,Nagira S,Yamamoto H,et al.Solid dispersion particles of amorphous indomethacin with fine porous silica particles by using spraydrying method[J].Int J Pharm,2005,293(1-2):155-164.
  • 10Friedrich H,Fussnegger B,Kolter KR.Dissolution rate improvement of poorly water-soluble drugs obtained by adsorbing solutions of drugs in hydrophilic solvents onto high surface area carriers[J].Eur J Pharm Biopharm,2006,62(2):171-177.

二级参考文献35

  • 1韩海岭,柴佩华,丁宇,王建新.Eudragit~ NM30D在双氯芬酸钠缓释骨架片中的应用[J].华西药学杂志,2008,23(4):399-401. 被引量：4
  • 2丁雪鹰,高申,缪春辉,管斐,陈宙艳,张仰眉.水分散体包衣制备奥昔布宁渗透泵片[J].中国药学杂志,2005,40(3):200-202. 被引量：4
  • 3向军涛,蒋琳兰.Eudragit NE水性包衣工艺制备氯化钾缓释片的研究[J].解放军药学学报,2007,23(4):265-267. 被引量：9
  • 4平其能,张灿.尤特奇.应用技术指南[M].北京:化学工业出版社,2009:1-9.
  • 5Abbaspour MR, Sadeghi F, Afrasiabi GH. Design and stu- dy of ibuprofen disintegrating sustained-release tablets comprising coated pellets[J]. Eur J Pharm~ Biopharm, 2008,68(3) : 747.
  • 6Azarmi S, Farid J, Nokhodchi A, et al. Thermal treating as a tool for sustained release of indomethacin from Eudragit RS and RL matrices[J], lnt J Pharm, 2002, 246 (1-2) : 171.
  • 7Abbaspour MR, Sadeghi F, Afrasiabi GH. Preparation andcharacterization of ibuprofen pellets based on Eudragit RS PO and RL PO or their combination[J]. Int J Pharm, 2005, 303(1-2):88.
  • 8Fan TY, Wei SL, Yan WW, et al. An investigation of pul- satile release tablets with ethylcellulose and Eudragit L as film coating materials and cross-linked polyvinylpyrrol- idone in the core tablets[J]. J Control Release, 2001, 77 (3):245.
  • 9E1-Kamel AH, Sokar MS, A1 Gamal SS, et al. Preparation and evaluation of ketoprofen floating oral delivery system [J]. lnt J Pharm, 2001,220 ( 1-2 ) : 13.
  • 10Onishi H, Oosegi T, Machida ~. Efficacy and toxicity of Eudragit-coated chitosan-succinyl prednisolone conjugate microspheres using rats with 2,4,6-trinitrobenzenesulfon- ic acid induced colitis[J], lnt d" Pharm, 2008, 358 (1-2) : 296.

共引文献19

同被引文献3

引证文献2

二级引证文献3

中南药学
2015年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部